Products & ReviewLife Sciences
SureSelect Cancer Tumor-Specific Assays
SureSelect Cancer Tumor-Specific assays offer genomic profiling for solid tumors from lung, colon, pancreas, kidney, or bladder tissue, to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), and translocations (TLs). These small cancer panels enable affordable tumor genomic profiling.
Request Pricing
Receive your quote directly from the manufacturer.
Powered by SureSelect XT HS2 library preparation and target enrichment reagents, the assays feature fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries. Automation options reduce hands-on time to maximize lab efficiency.
For Research Use Only. Not for use in diagnostic procedures.
- Small cancer panels of approximately 50 genes each for lung, colon, pancreas, bladder, and kidney, based on subsets of gene content from the SureSelect Cancer CGP assay
- Compatibility with low throughput sequencers (Illumina MiSeq and MiniSeq) for lower cost tumor genomic profiling
- Globally curated, clinically relevant biomarker content
- Walkaway convenience using the benchtop Agilent Magnis NGS Prep system with only 15-min hands on time
- For gene fusion detection, modular workflow allows the option to combine a SureSelect Cancer Tumor-Specific DNA assay with the SureSelect Cancer CGP RNA assay (80 genes) together in the same sequencing run
- Start with input as low as 10 ng DNA (recommended 50 ng) to enable profiling of more samples
- Fast hybridization (90 minutes) for library preparation in a single day
- Flexible data analysis options, including Agilent Alissa, customer in-house, and third-party software
